Sydney Uni spinout lands deal to develop psychiatric drugs
Kinoxis Therapeutics has announced a strategic partnership with Boehringer Ingelheim for the development of first-in-class oxytocin-targeting precision psychiatry treatments.
Source: labonline.com.au